OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients

Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its ...

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company ...
Yahoo Finance

OSE’s UC therapy prompts 16% clinical remission after ten weeks

France-based OSE Immunotherapeutics’ (OSE) Phase II CoTikiS study of lusvertikimab has met primary and secondary endpoints, showing high rates of clinical and endoscopic remission after ten weeks in ...
TMCnet

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting

Nantes, France, April 15, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage ...
Yahoo Finance

OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®

Nantes, France, March 2, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced a targeted realignment of its R&D portfolio to reinforce execution of its ...
Business Wire

OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key ...
Business Wire

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

€18.7 million available cash as of December 31 st, 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1, nor ...
FierceBiotech

Revolution via resolution: AbbVie pays $48M for OSE's preclinical chronic inflammation drug

AbbVie is talkin’ bout a resolution. The Big Pharma has bet $48 million on OSE Immunotherapeutics’ antibody platform, handing the biotech the upfront fee and dangling another $665 million in ...
PharmiWeb

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth

Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive ...